Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06679855 · ClinicalTrials.gov registry record · Phase 3
Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial
A Phase 3 study of Post-ligation Cardiac Syndrome, sponsored by NICHD Neonatal Research Network.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 316
- Enrollment target
- 19
- Study locations
NCT06679855: Recruiting Phase 3 study of Post-ligation Cardiac Syndrome, sponsored by NICHD Neonatal Research Network.
NCT06679855 is a Phase 3 study of Post-ligation Cardiac Syndrome that is actively recruiting participants, run by NICHD Neonatal Research Network. The registered enrollment target is 316 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (59% lower). The trial reports 19 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06679855, a Phase 3 study of Post-ligation Cardiac Syndrome, is actively recruiting participants, sponsored by NICHD Neonatal Research Network.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 316 participants
- Enrollment target
- 19
- Study locations
Study Summary
The goal of this Phase 3, randomized, masked clinical trial is to is to find out whether milrinone, when given to infants after PDA closure, will help the heart work better by supplying oxygen to the lungs and tissues. The main questions it aims to answer are: 1. to determine if milrinone decreases the risk of death or PLCS within 7 days of the procedure, compared to standard treatment; and 2. to determine the effects of milrinone on two-year survival and neurodevelopmental outcome.
Primary Outcome
Composite outcome of post-ligation cardiac syndrome (PLCS) or death within 7 days of PDA closure. Onset within 48 hours but may last up to 7 days.
Conditions Studied
Interventions
- DRUG Placebo infusion
- DRUG Milrinone infusion
Study Locations (19)
California
- Children's Hospital of Orange County - Orange
- Stanford University - Palo Alto
- Sharp Mary Birch Hospital for Women & Newborns - San Diego
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Case Western Reserve University - Cleveland
Texas
- University of Texas Southwestern - Dallas
- University of Texas at Houston - Houston
Alabama
- University of Alabama - Birmingham - Birmingham
Georgia
- Emory University - Atlanta
Illinois
- Northwestern Lurie Children's Hospital of Chicago - Chicago
Iowa
- University of Iowa - Iowa City
Massachusetts
- Boston Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 316 participants |
| Start Date | 2025-06-13 |
| Est. Completion | 2029-06-30 |
| Phase | Phase 3 |
What NCT06679855 shows while recruiting
NCT06679855 is an interventional study that assigns participants to a tested intervention. The registered 316 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (59% lower).
The record links to 1 condition, with Post-ligation Cardiac Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo infusion is the first listed.
NCT06679855 lists 19 locations in 15 states (California, Ohio, Texas).
Frequently Asked Questions
What is clinical trial NCT06679855 about?
NCT06679855 is a clinical study titled "Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial". The goal of this Phase 3, randomized, masked clinical trial is to is to find out whether milrinone, when given to infants after PDA closure, will help the heart work better by supplying oxygen to the lungs and tissues. The main questions it aims to answer are: 1. to determine if milrinone decrease...
What is the current status of trial NCT06679855?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 316 participants. The study started on 2025-06-13. Estimated completion is 2029-06-30.
What conditions does trial NCT06679855 study?
This clinical trial studies the following conditions: Post-ligation Cardiac Syndrome.
What interventions are being tested in trial NCT06679855?
The interventions under investigation include: Placebo infusion (DRUG), Milrinone infusion (DRUG).
Who is sponsoring clinical trial NCT06679855?
This trial is sponsored by NICHD Neonatal Research Network, which has 61 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06679855 being conducted?
This trial has 19 study locations across Alabama, California, Georgia, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06679855's enrollment target sits among peer trials
316 1091st of 2000 higher than 909 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04256317 · 316 participants · Phase 2
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- NCT04787042 · 316 participants · Phase 1
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
- NCT04802759 · 316 participants · Phase 1
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
- NCT05464056 · 316 participants · NA
BUILT Family Lifestyle Program for Children with ADHD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI